Company intelligence / Profile preview

Stemgent

Beltsville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

Stemgent, now a REPROCELL brand, pioneered mRNA-based and self-replicative RNA reprogramming technology to produce high-quality iPSCs for research and therapeutic development. Its products and services are broadly used by academia and industry to enable basic and translational research, and preclinical R&D, but it does not have commercial therapeutic programs in clinical trials.

Modalities: Small moleculeAntibodyGrowth factorStem cell therapyInduced pluripotent stem cell derived therapyRNA-based therapy
Industry: Non-Drug Biotech

Partnerships

Miltenyi BiotecTransposagen BiopharmaceuticalsPfizer

Beyond the preview

Go deeper on Stemgent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stemgent.

Explore the full profile